Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe 2.5 mg Mounjaro KwikPen delivers approximately 0.5 ml per dose. Each pen contains four weekly doses, so the total fill volume is around 2 ml. Knowing how many ml is in 2.5 mg of Mounjaro is a natural question — but the volume itself isn't something you need to adjust, measure or worry about. The pen does all of that for you. Mounjaro is a prescription-only medicine, and the dose you use is determined by a GPhC-registered prescriber based on your individual assessment, not selected by you from a syringe. What matters clinically is the milligram amount (2.5 mg), not the volume in the barrel. The sections below explain why, and what the 0.5 ml figure actually tells you about how the pen is designed.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Mounjaro KwikPens are formulated at a concentration of 5 mg of tirzepatide per ml across every available strength. That single fact answers the volume question precisely: 2.5 mg divided by 5 mg/ml gives you 0.5 ml per dose. You can cross-check this in the Mounjaro SmPC on the electronic Medicines Compendium (eMC), which lists the formulation details for each pen.
The same arithmetic applies as treatment progresses. The 5 mg pen delivers 1 ml per dose, and the 7.5 mg pen delivers 1.5 ml, each step up in dose adds 0.5 ml, because the concentration stays fixed. The pen's label and the dose counter do the tracking for you, but understanding the maths helps if you're curious about what's in the device you're using.
0.5 ml is a small volume. For context, it's roughly the same as ten drops of water. Subcutaneous injections at this scale are designed to be comfortable, the volume disperses easily into the fatty tissue just beneath the skin.
It's worth pausing on why this matters. Many people starting Mounjaro come from a background of no experience with injections at all. Seeing a pre-filled device and wondering what's inside it, and whether you're doing it right, is completely understandable.
The KwikPen is a multi-dose device. Its barrel contains approximately 2 ml of solution, pre-set to release exactly 0.5 ml each time the injection button is pressed fully. You attach a fresh needle, select an injection site (abdomen, thigh or upper arm), press the pen against the skin and hold the button down until the dose counter advances. You do not draw up fluid, you do not set a volume dial, and you do not see the injection happen, the mechanism is enclosed. The volume per single Mounjaro dose is locked in by the pen's engineering.
After each weekly injection the dose counter decreases by one. Once it reaches zero the pen is empty and should be disposed of in a sharps container. The NHS tirzepatide patient page has a clear overview of injection technique if you want a plain-English walkthrough alongside the Patient Information Leaflet.
The reason Mounjaro treatment begins at 2.5 mg isn't that the volume is small) it's that the starting dose is calibrated to give your body time to adjust before moving to doses with more clinical effect. Nausea and other gastrointestinal effects are most common in the early weeks, and the lower starting dose reduces their intensity for most people. Volume plays no role in that; the pharmacology does.
As treatment progresses, a prescriber reviews whether you're tolerating the current dose well enough to increase it. If you're thinking about what comes next, the page on what happens when you increase your Mounjaro dose covers how that process typically unfolds. For people curious about the broader dose range (and why the pen sequence is structured the way it is) the reason Mounjaro has an extra dose step is explained separately.
The clinical decisions around milligrams belong with your prescriber. The volume, by contrast, is fixed and automatic. Trying to estimate or alter it yourself serves no clinical purpose and isn't something the pen is designed to allow.
One question that comes up occasionally: does the concentration change at higher doses? It doesn't. From the 2.5 mg pen right through to the 15 mg pen, the solution is always 5 mg/ml. That consistency means the pen mechanism stays the same, you use it the same way at every strength. The only thing that changes is how much solution is released per press. If you want a side-by-side picture of how the 2.5 mg pen compares with the next step up, the 5 mg Mounjaro pen overview sets out what shifts at that strength.
For a broader look at the treatment, including how private access works and what a consultation involves, the Mounjaro treatment overview is the right starting point. If cost is on your mind, the UK Mounjaro price comparison explains what legitimate private pricing typically includes and why the figure varies between providers. At nume, every prescription is reviewed personally by a clinician, a real person reads your answers the same day, not an automated system. If that sounds like what you're looking for, you're welcome to speak to our prescribers through a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.